Oncology · PI3K InhibitorRegulatory Approvalregulatorynear-term

FDA Approves REVTORPYK (GEDATOLISIB) for Celcuity Inc.

Importance8/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/18/2026, 6:30:59 AM

Assessment confidence: 73% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of REVTORPYK (gedatolisib) is a significant milestone for Celcuity Inc., enhancing its position in the competitive oncology landscape. This approval necessitates close monitoring of market dynamics and competitive responses as the drug enters the market. Regulatory context from FDA (FDA AP — REVTORPYK (ORIG)) supports the near-term read. Assessment grounded in 22 ranked evidence items (14 high-relevance).

Strategic Assessment

Strategic focus on market entry strategies and potential partnerships to maximize the drug's launch impact. The strongest clinical anchor is Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials (ClinicalTrials.gov), moderate corpus alignment. In Oncology · PI3K Inhibitor, 2 regulatory and 7 competitive items passed relevance filtering for REVTORPYK.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility (Pfizer) — sponsor/company relevance (pfizer). FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — REVTORPYK (ORIG) (FDA). Entity match (revtorpyk); Regulatory pathway relevance (nda). The approval signifies compliance with FDA standards, which can influence future regulatory strategies for Celcuity Inc. and similar oncology products.

Key Risks

Elevated high regulatory exposure for REVTORPYK could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.

Key Opportunities

The approval opens potential revenue streams for Celcuity Inc. in the oncology sector, but market reception and competitive responses will determine its overall impact on market share.
Upside for REVTORPYK may improve if PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Upside for REVTORPYK may improve if A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · Breast Cancer · Regulatory Approval · This approval positions gedatolisib as a new treatment option in a competitive landscape dominated by existing therapies for HR-positive breast cancer.
Strategic focus on market entry strategies and potential partnerships to maximize the drug's launch impact.

What Would Change This Assessment

This becomes more urgent if Monitor market reception, sales performance, and any emerging competitive responses from other oncology therapies.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — REVTORPYK (ORIG)
FDAhigh relevance
Entity match (revtorpyk); Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Real-World Study of IL-23 Inhibitors in Active Crohn's Disease
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
FDA Grants Approval for Dr. Reddy's Venetoclax ANDA214733
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA approves gedatolisib with fulvestrant for HR-positive, HER2-negative breast cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for Tecentriq Supplement Application
Humanexa Signalsmedium relevance
Moderate corpus alignment

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Recent advances in functional studies of coronavirus NSP13 helicase and challenges in inhibitor development.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Self-perceived learning outcomes of academic detailing discussing rational therapy with proton pump inhibitors among general practitioners in Norway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
UBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

REVTORPYK

Commercial impact

medium

The approval opens potential revenue streams for Celcuity Inc. in the oncology sector, but market reception and competitive responses will determine its overall impact on market share.

Regulatory impact

high

The approval signifies compliance with FDA standards, which can influence future regulatory strategies for Celcuity Inc. and similar oncology products.

What to watch

Monitor market reception, sales performance, and any emerging competitive responses from other oncology therapies.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.